Pfizer will cut around 330 jobs in Italy at its Sicily plant, ​labour unions said on Wednesday, making ‌the US drugmaker the ...

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Ten consecutive earnings beats and a shrinking COVID hangover have Wall Street split on whether Pfizer deserves a breakout or ...

TUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, ...

FDA approved Pfizer's Tukysa combo as front-line maintenance for metastatic HER2-positive breast cancer on Oct. 7, 2026; a ...

Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, ...

If you've been looking for high-yield stocks, Pfizer (PFE-1.40%) may have crossed your radar screen. As shares of the pharma ...

Pfizer said the Food and Drug Administration approved Tukysa as a front-line maintenance treatment for people with a form of breast cancer.

Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return ...

Pfizer (PFE) said Wednesday that the US Food and Drug Administration has approved Tukysa in combination with trastuzumab and pertuzumab for the maintenance treatment of metastatic ...

Florida Attorney General James Uthmeier filed a lawsuit Thursday against Pfizer Inc., alleging unfair and deceptive marketing ...